UK markets open in 6 hours 54 minutes

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.8300-0.0800 (-2.75%)
At close: 4:00PM EDT
2.8201 -0.01 (-0.35%)
After hours: 07:51PM EDT
Sign in to post a message.
  • H
    Hannibal
    The amount of shorts bashing here on Yahoo, reminds me of the months april / may earlier this year . You know, right before we went from 1,7$ to 9,80$ . They only come out if they're scared. We're good
  • a
    alan
    so. pie ! what does that tell you ! do you get the feeling this company is just a trinket on his key chain ? my gut feeling is , if this. elite over bloated head case DOSENT move quick enough, the things in. ATOS. pipeline will. dry up ! die on the vine ! be overshadowed by other more aggressive companies! this QUQY, is to self absorbed!! ATOSA. BETTER. be a buy out or this will just spin it's wheels.
  • P
    Piescoffer99
    Wow Quay has released a video today encouraging women to have regular mammograms. Has he forgotten he runs a company with shareholders?
  • M
    Manny
    Piescoffer99 comes here to pump OCGN. Unless their vaccine gets approved in the US they will not make any money on it. They only get paid if it makes money in the US. You already have tow vaccines approved here with two of them much better. He doesn't care about anyone but himself. He tries to lead rookies and those of low IQ into his money losing stock picks!

    Even if the pandemic continues for a year or two, other vaccines will likely continue to dominate the market in developed countries while Covaxin could, at best, carve out a very tiny share of this space. And whatever sales it generates will have to be shared with Bharat Biotech. Covaxin's best shot, in my view, is to make waves in countries where vaccines aren't as readily available.

    But that wouldn't help Ocugen. And to make matters worse, none of the company's other pipeline programs have even made it to a phase 2 study yet. Any regulatory setback related to Covaxin could send Ocugen's stock spiraling down. Putting all this together, this biotech stock does not look like a particularly attractive investment at the moment. Investors would do better to look elsewhere.
  • N
    Ninja Trader
    ATOS hitting bullish territory. If the trend line persists we can see upwards of $6-7 within the month.
  • M
    Maruthi
    Endoxifen is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group. It is an active metabolite of tamoxifen and has been found to be effective in patients that have failed previous hormonal therapies (tamoxifen, aromatase inhibitors, and fulvestrant). The prodrug tamoxifen is metabolized by the CYP2D6 enzyme to produce endoxifen and afimoxifene (hydroxytamoxifen).
    Astra's Tamoxifen has limitations. When ATOS Endoxifen in market, no one will buy Tamoxifen, that's why Astra is playing πŸ˜‰
    We know how major companies play in markets. Just wait guy...we all will become rich with AtossaTherapeutics πŸ‘
  • A
    Alec
    probably rock bottom price right now. I think even without news this will go up but with news this will sky rocket
  • B
    Bill
    Piescoffer99 turned me into a short. Never made so much money going against every thing he goes long.
    Made a fortune, I mean millions shorting PSFE ATOS SAVA OCGN RMO. Please keep them coming Piescoffer99. I am starting to like you!
  • B
    Bill
    You notice the aliases that want me to go all belong to Piescoffer99. He doesn't like being exposed.
    He is all shrunk up like he just got out of a cold pool!
  • r
    royce
    Red days are buying opportunities if you believe in the companies management and its pipeline
  • B
    Bill
    SAVA down another 3.5% OCGN down another 4,4% ATOS down. That Piescoffer99 really knows how to pick em! Hahahahaaha
  • a
    alan
    ok! on this side we have our resident. shorters!
  • V
    Ven
    $7.75 with news release.
  • M
    Maruthi
    Endoxifen is one of the best medicines in the world. Probably the institutions want to buy this share at low price.
    But we would see between $3 to $4 this week. Just wait for some company suddenly buy in millions.
  • S
    Saad
    Only one cent to my target $2.72, it should rebound the question can it pass $3.94 this week, I doubt it we need good news for that.
  • B
    Bill
    Piescoffer99 please share with us your news stock pick. We can hardly wait.
    PSFE AEVA OCGN SAVA ATOS RMO this list is long and filled with your failures.
  • a
    alan
    is shakes back in ? or I BET here's looking for more solid action ? this may be just a base bounce ! am I correct ? πŸ™ŠπŸ™ˆπŸ™‰πŸ€ 
  • a
    alan
    my friend! he was 60 yrs old! WAS IN TOP SHAPE! A WORLD NOTED. HUNTING FISHING GUIDE !!
  • B
    Bobbie
    A stock I like but would like to get in a little cheaper is MTTR. I bought it around $14.20 and sold around $21.80. Like to get back in under $18. Anyone who deals in real estate is familiar with this company.
    I used their technology to look at the yacht I put an offer in on.
  • o
    ohad
    where is james?? he promised us reversal